
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals (NASDAQ:PMVP) is dedicated to the discovery and development of precision medicines for cancer treatment. With a focus on leveraging the power of p53, the body's natural tumor suppressor protein, Pmv aims to unlock new therapeutic options for patients. The company's projects primarily revolve around creating small molecule therapies designed to restore the normal function of mutant p53 proteins. Their objective is to advance these groundbreaking treatments through clinical trials with the ultimate goal of offering new hope to individuals battling cancer. This pursuit not only reflects Pmv's commitment to innovation in oncology but also underscores their dedication to improving patient outcomes through scientific excellence.
Snapshot
Operations
Products and/or services of Pmv Pharmaceuticals Inc
- PC14586, a small molecule reactivator of p53 Y220C mutant.
- Research in targeted therapies for cancer with p53 mutations.
- Pipeline development for small molecule therapeutics in oncology.
- Advancements in precision medicine for cancer treatment.
- Collaborations with leading biotech firms to enhance drug discovery.
- Services in drug development and clinical trial support for cancer therapies.
Pmv Pharmaceuticals Inc executive team
- Dr. David H. Mack Ph.D.Co-Founder, CEO, President & Director
- Dr. Arnold J. Levine Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory Board
- Mr. Michael CarulliChief Financial Officer
- Dr. Deepika Jalota Pharm.D.Chief Development Officer
- Mr. Robert Ticktin J.D.General Counsel, COO & Company Secretary
- Mr. Tim SmithSenior VP and Head of Corporate Development & Investor Relations
- Ms. Crystal ZuckermanVice President of Human Resources
- Dr. Binh Vu Ph.D.Senior Vice President of Drug Discovery & CMC
- Dr. Marc Fellous M.D.Senior VP and Head of Clinical Development & Medical Affairs
- Ms. Laura De LeonVP & Head of Clinical Operations